Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana

Humana's stock looked to rally Monday. And Mizuho analyst Ann Hynes said she believes a buyout by Cigna Group is likely — it's just a matter of timing.

Potential Cigna buyout of Humana is a ‘when,' not an ‘if,' analyst says

54 community-based organizations receive funds to support the dietary needs of older adults BLOOMFIELD, Conn. , Oct. 21, 2024 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), is investing $600,000 in community-based organizations this fall to address food insecurity among older Americans.

Cigna Healthcare Commits $600,000 To Reduce Food Insecurity Among Seniors

U.S. health insurer Cigna Group has revived efforts to merge with smaller rival Humana after abandoning the pursuit late last year, Bloomberg News reported on Friday, citing people familiar with the matter.

Cigna resumes merger discussions with Humana, Bloomberg News reports

In trading on Friday, shares of The Cigna Group crossed below their 200 day moving average of $340.21, changing hands as low as $338.60 per share. The Cigna Group shares are currently trading off about 3.8% on the day.

Cigna Breaks Below 200-Day Moving Average

Molina Healthcare

UnitedHealth Group

The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.

4 HMO Stocks to Watch Despite Continued Industry Headwinds

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Cigna (CI) is a Top Value Stock for the Long-Term

CVS Health

The healthcare company said Chair Lina Khan, Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro Bedoya through public statements show they have prejudged the matter at hand.

CVS, Cigna Seek to Disqualify FTC Officials in Insulin Case Over Alleged Bias

Coterra Energy

For dividend-paying companies, maintaining dividend growth is an essential way to demonstrate to investors that a firm is stable and enjoys long-term profitability. Dividend growth is also attractive to investors because it means an increasing passive income stream through stock ownership.

3 Dividend Growth Stocks Set to Supercharge Your Portfolio

Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?

BLOOMFIELD, Conn. , Oct. 3, 2024  /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day.

The Cigna Group's Third Quarter 2024 Earnings Release Details

AbbVie

Bank of America

Bank of New York Mellon

Blackrock Inc

Caterpillar

Citizens Financial Group

Deere & Company

Discover

Fastenal

Fifth Third Bancorp

Goldman Sachs

Interpublic Group of Companies

JPMorgan Chase & Co

KeyCorp

Lamb Weston Hlds

Morgan Stanley

Omnicom Group

Otis Worldwide

PNC Financial Services

Regions Financial

Ralph Lauren

Charles Schwab

Simon Property Group

Steel Dynamics

Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.

Dividend Stocks With Strong Q4 Seasonality

CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.

CVS, Cigna unveil Medicare Advantage plans for 2025

Plans available for every lifestyle and budget, including Medicare Advantage (MA) plans, Medicare Supplement plans, and standalone Prescription Drug Plans, all with competitive premiums and benefits. Many MA plans available for $0 premium; some give customers money back on their Social Security check.

Cigna Healthcare Offers Medicare Customers Value, Stability and Choice with 2025 Plans

Third annual Vitality In America study shows more people achieving high vitality, driven by improved sense of energy.  While Gen Z adults continue to have the lowest overall vitality, they are feeling more confident, capable, and optimistic.

The Cigna Group Issues 2024 Vitality In America Report, Revealing Increased Optimism Among Young Americans and Offering Insights on Workforce Health and Engagement

The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.

Cigna: This Dividend Grower Could Be Worth Buying Now

The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.

Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?

Allstate

Broadcom

American Express

Carlisle Companies

Cintas Corp

D.R. Horton

Dick's Sporting Goods

Comfort Systems USA

Hartford Financial Services Group

Hamilton Lane

KLA-Tencor

Eli Lilly

Monolithic Power Systems

NRG Energy

NetApp

Universal Display

PulteGroup

Tetra Tech

Wingstop

This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - September 2024

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.

UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?

Express Scripts was the first to cap out-of-pocket costs for insulin medications at $25 for a 30-day supply in 2019, well before the government took action ST. LOUIS , Sept.

Express Scripts Comments on FTC's Reckless Insulin Action

The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.

UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'

The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.

Explainer: Why are US pharmacy benefit managers under fire?

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients.  The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.

FTC sues drug middlemen for allegedly inflating insulin prices

News for Cigna Stock (CI)